A196300 Share Price Performance
₩6,410.00
-6960.00 (-52.06%)
Price ₩6,410.00
Share Pricen/a
HLB Pep Co., Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A196300 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
HLB Pep Co., Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -568.49
- -17.92%
- -109.32%
- 58.4%
About A196300
- Founded
- 2000
- Employees
- n/a
- CEO
- WebsiteView website
HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of viral infection; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria. In addition, it is involved in the development of AGM-212 indicated for the treatment of Type 2 Diabetes; AGM-217 indicated for the treatment of Type 2 diabetes and obesity; and AGM-260 indicated for the treatment of Ulcerative colitis. The company was formerly known as Anygen Co., Ltd. and changed its name to HLB Pep Co., Ltd. in April 2025. The company was founded in 2000 and is headquartered in Gwangju-si, South Korea.
